Articles Related to monoclonal
Immunoprophylaxis against Respiratory Syncytial Virus Infections
Respiratory Syncytial Virus is an etiological cause of lower respiratory tract infections. Due to the controversial therapeutic approach, it has a significant share in the causes of hospitalizations and even fatal outcomes concerning children up to two years of age. The elderly patients, especially the immune compromised and those with co-morbidities, are at a great risk of developing severe conditions because it is often not considered as pathogen. Those are the reasons which determine the necessity of prophylaxis of the abovementioned target groups of patients - children up to two years of age and adults over 65
years of age.
Clinical Features and Management of Eosinophilic Asthma
Asthma is a common chronic airway disease affecting about 334 million people worldwide, and an estimated 7 million children
globally. Approximately 10% of patients with asthma have severe refractory disease, which is uncontrolled despite using high doses
of inhaled corticosteroids and other modifiers. Among these patients are patients with eosinophilic asthma. Eosinophilic asthma is a
phenotype of asthma that is usually very severe and persistent, with frequent exacerbations. It is characterized by the presence of high
levels of eosinophils, and CD+4 Th2 cells in the lungs and airways. Eosinophils play a pivotal role in the pathogenesis and severity
of asthma. Most patients with eosinophilic asthma respond to the classic stepwise guided treatment. However, 50% of patients with
eosinophilic asthma are refractory to corticosteroids and long-acting β2-agonists. Currently, there are targeted personalized biologics
for these patients. These biotherapeutics include IgE, interleukin and interleukin receptor monoclonal antibodies,they have added
advantageous steroid-sparing effects.
Monoclonal Antibodies for the CIGB-552 Antitumor Synthetic Peptide Quantification
The CIGB-552 peptide is a synthetic peptide that exerts cytotoxic effect on tumor cells. Thus, CIGB-552 peptide quantification in patient samples is crucial for assessing the treatment efficacy. Therefore, this study describes the generation and characterization of monoclonal antibodies (mAb) directed against the CIGB-552 peptide to be used in a quantification assay in further pharmacokinetic studies in humans. In this sense, the CIGB.552-H294 mAb specificity was evidenced only against the CIGB-552 peptide and a metabolite of 17 amino acids resulting from the CIGB-552 peptide degradation detected in mouse sera.
IL-8 Regulates Epithelial-Mesenchymal Transition through pERK1/2 in AGS Cells
The aim of this project was to evaluate the influence of inflammatory cytokines IL-1β and IL-8 on gastric epithelial-mesenchymal transition in gastric epithelial cells.
Anti-GnRH Receptor Monoclonal Antibodies, First-In-Class GnRH Analog
A monoclonal antibody (Mab) designated as GHR106 was generated against the extracellular domain (N1-29 synthetic peptide) of human gonadotropin releasing hormone (GnRH) receptor. It is a first-in-class GnRH analog and can serve as a drug candidate for potential applications in the treatment of human cancers and/or fertility regulations.
The Emergence of Multiple Myeloma in a Patient with Essential Thrombocythemia: A Case Report
Multiple myeloma is a neoplastic disease characterized by neoplastic proliferation of plasma cells and monoclonal protein expression and related tissue damage.In the presence of overt clinical signs, the disease can easily be diagnosed, however in order to diagnose atypical cases, further investigation is needed with high clinical suspicion.
